Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across Italy.
Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease / C. Bezzio, G. Franchellucci, E.V. Savarino, M. Mastronardi, F.A. Caprioli, G. Bodini, A. Variola, F. Scaldaferri, F. Furfaro, E. Calabrese, M.B. Principi, G. Biscaglia, M. Marzo, A. Michielan, C. Cavalli, A. Aratari, M. Campigotto, L. Ceccarelli, M. Cappello, S. Saibeni, P. Balestrieri, A. Soriano, V. Casini, L. Bertani, B. Barberio, F.S. Conforti, S. Danese, A. Armuzzi. - In: CROHN’S & COLITIS 360. - ISSN 2631-827X. - 6:4(2024 Oct 24), pp. otae060.1-otae060.5. [10.1093/crocol/otae060]
Upadacitinib in Patients With Difficult-to-Treat Crohn's Disease
F.A. Caprioli;
2024
Abstract
Upadacitinib has recently been approved for treating Crohn's disease (CD). Here, we report on the effectiveness and safety of upadacitinib in a cohort of patients with difficult-to-treat CD being cared for at clinical centers across Italy.
| File | Dimensione | Formato | |
|---|---|---|---|
|
otae060.pdf
accesso aperto
Tipologia:
Publisher's version/PDF
Dimensione
410.54 kB
Formato
Adobe PDF
|
410.54 kB | Adobe PDF | Visualizza/Apri |
Pubblicazioni consigliate
I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
